DeepMed Research

The New York State Psychiatric Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1895-01-01

Employees: 251

Market Cap: -

Website: http://www.nyspi.org

Clinical Trials

Study of Buprenorphine Maintenance Treatment for Opioid Dependence in Primary Care

Completed

Conditions: Heroin Dependence
Opioid-Related Disorders
Substance Abuse, Intravenous

First Posted Date: 2007-05-09

Last Posted Date: 2019-04-23

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 30

Registration Number: NCT00471042

Locations: 🇺🇸
Columbia University/New York State Psychiatric Institute, New York, New York, United States

Pre-Treatment Positron Emission Topography Scanning for Increasing Success in Antidepressant Treatment

Not Applicable

Completed

Conditions: Depression

Interventions: Drug: Escitalopram
Drug: Desipramine

First Posted Date: 2007-04-04

Last Posted Date: 2019-03-19

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 37

Registration Number: NCT00456014

Locations: 🇺🇸
Columbia University/New York State Psychiatric Institute, New York, New York, United States

Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism

Phase 4

Terminated

Conditions: Depression
Alcoholism
Suicidal Behavior

Interventions: Drug: fluoxetine
Drug: bupropion

First Posted Date: 2007-03-19

Last Posted Date: 2021-08-04

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 5

Registration Number: NCT00449007

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Paroxetine/Bupropion in Suicide Attempters/Ideators With Major Depression

Phase 4

Terminated

Conditions: Depression

Interventions: Drug: Paroxetine
Drug: Bupropion

First Posted Date: 2007-01-31

Last Posted Date: 2018-10-30

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 101

Registration Number: NCT00429169

Locations: 🇺🇸
Columbia University/New York State Psychiatric Institute, New York, New York, United States

Parent-Provider Intervention for Improving Medication Adherence in Children With Attention Deficit Hyperactivity Disorder

Not Applicable

Withdrawn

Conditions: Attention Deficit Disorder With Hyperactivity

First Posted Date: 2007-01-31

Last Posted Date: 2013-04-23

Lead Sponsor: New York State Psychiatric Institute

Registration Number: NCT00429221

Prozac Treatment of Major Depression: Discontinuation Study

Phase 4

Completed

Conditions: Major Depression

First Posted Date: 2007-01-26

Last Posted Date: 2011-12-15

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 627

Registration Number: NCT00427128

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Open-label Ziprasidone Study for Psychosis Treatment in Adolescents

Phase 3

Completed

Conditions: Depressive Disorder, Major
Schizophreniform Disorder
Bipolar Disorder
Psychosis
Schizoaffective Disorder

Interventions: Drug: Ziprasidone

First Posted Date: 2007-01-15

Last Posted Date: 2017-01-13

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 8

Registration Number: NCT00421954

Locations: 🇺🇸
NYSPI, New York, New York, United States

A Placebo-Controlled Study of Mixed Amphetamine Salts and Topiramate for the Treatment of Cocaine Dependence

Phase 2

Completed

Conditions: Cocaine Dependence

Interventions: Drug: Adderall-XR and Topiramate
Drug: Placebo

First Posted Date: 2007-01-12

Last Posted Date: 2019-04-24

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 81

Registration Number: NCT00421603

Locations: 🇺🇸
STARS, New York, New York, United States

Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients

Phase 2

Completed

Conditions: Benzodiazepine Dependence
Opioid Dependence

Interventions: Drug: Placebo
Drug: Gabapentin

First Posted Date: 2007-01-11

Last Posted Date: 2019-04-24

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 19

Registration Number: NCT00420771

Locations: 🇺🇸
Bridge Plaza Treatment and Rehabilitation Clinic, Long Island City, New York, United States

Antipsychotic Discontinuation in Alzheimer's Disease

Phase 4

Completed

Conditions: Alzheimer Disease
Psychotic Disorders
Agitation
Aggression

Interventions: Drug: risperidone

First Posted Date: 2007-01-01

Last Posted Date: 2013-04-24

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 180

Registration Number: NCT00417482

Locations: 🇺🇸
WLA VA Medical Center/UCLA, Psychiatry, Los Angeles, California, United States
🇺🇸
University of Iowa College of Medicine, Iowa City, Iowa, United States
🇺🇸
Tuscaloosa VA Medical Center, Department of Psychiatry, Tuscaloosa, Alabama, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy